Next Pharmaceuticals Reveals Nexrutine(R) Prevents Prostate Cancer Progression in Pre-clinical Animal Model
5/2/2007 1:10:32 PM
SALINAS, Calif.--(BUSINESS WIRE)--Next Pharmaceuticals announced today the results of a study that an over-the-counter non-toxic botanical supplement, Nexrutine (Phellodendron amurense), prevents the progression of prostate tumors in mice. The study was conducted in the laboratory of Dr. Pratap Kumar, Department of Urology at the University of Texas Health Science Center at San Antonio and is published in the May 1, 2007 edition of Clinical Cancer Research, a prestigious peer-reviewed health journal from American Association for Cancer Research (AACR).
comments powered by